Rennova Health, Inc. · OTC:RNVA

Rennova Health — CollabRx — IPO Roadshow (November 2014)

22 slides from Rennova Health's IPO roadshow presentation, Nov 18, 2014

Slide 1: CollabRx: Empowering Cancer Care
NASDAQ: CLRX CollabRx: Empowering Cancer Care Expert systems for genomics-based cancer treatment planning Issuer Free Writing ProspectusFiled Pursuant to Rule 433Registration No. 333-199477November 18, 2014
Slide 2: Safe Harbor
* Safe Harbor When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Importan
Slide 3: Free Writing Prospectus Statement
* Free Writing Prospectus Statement CollabRx, Inc. has filed a registration statement on Form S-1 (Registration No. 333-199477) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. A copy of the preliminary prospectus describing the terms of t
Slide 4: Overview of CollabRx
Overview of CollabRx A clinical decision-support company for precision oncologyWe translate expert knowledge about complex molecular medicine and make it relevant, accessible and actionable for practicing physiciansNot a lab – we focus on data interpretation, reporting and downstream analytics for c
Slide 5: Oncologists are our market
Oncologists are our market Automated, SaaS reporting service for complex NGS panelsExpert-vetted Actionability FrameworkXML data or physician-ready reportsVolume-based subscription / per test fee GVA™ Service “Expert systems” for treatment planning (Therapy Finders™)Relevant medical news as it break
Slide 6: Newly emerging market for genomic-based testing in cancer
* Newly emerging market for genomic-based testing in cancer Addressable US market ~ 13 million patients7 million (55%) with a strong genetic association*1.7 million new US patients in 2013 and 14 million globally*Growing to almost 3 million new US patients each year by 2050**Each day approximately 1
Slide 7: Need to address rapidly changing science and standards in oncology
Need to address rapidly changing science and standards in oncology “Our patients rely on us to guide them in this new landscape of molecular oncology. But the field is just changing too quickly. We simply do not have enough hours in the day to see patients and stay abreast of the field.” Source: Com
Slide 8: GVA focused on knowledge-based portions of clinical genetic testing workflow
GVA focused on knowledge-based portions of the clinical genetic testing workflow CollabRx Hospital Lab or Reference Lab * © Copyright 2014 CollabRx, Inc. - All Rights Reserved NASDAQ CM: CLRX
Slide 9: Therapy Finders make expert knowledge available at the office and at home
Therapy Finders™ make expert knowledge available at the office and at home Current Therapy Finders for Lung, Colorectal, and Metastatic Breast cancers and Melanoma Recently launched CancerRx mobile app includes Therapy Finders and MedPage Today newsfeed * © Copyright 2014 CollabRx, Inc. - All Rights
Slide 10: Combining in-house and external experts into a knowledge resource
* Editorial Boards& Guidelines Knowledge Base of Treatment Models In-House KnowledgeExperts Combine in-house and external experts to create a unique knowledge resource Representative Sources of Guidelines Representative Available Data Sources: © Copyright 2014 CollabRx, Inc. - All Rights Reserved NA
Slide 11: Over 75 expert advisors from leading institutions
Melanoma Melanoma Lung Breast Breast Colorectal Sarcoma Leukemia Prostate Pancreas Pan Cancer Breast Over 75 expert advisors from leading institutions provide best practice insights Representative institutional affiliations of advisors: An unprecedented network of uncompensated volunteers to advance
Slide 12: Minutes Not Days: GVA System
Minutes Not Days GVA System: Automated, scalable, contextualized assembly of content for labs entering the genomic testing market in cancer Platform for interpretation and reporting Testing and QA Project management Support Build/ deploy policies Content updates Hosting Availability Documentation Ap
Slide 13: Competitive Strengths
Competitive Strengths Proprietary knowledgebase is focused on actionable information for physiciansFocus is on providing actionable information that physicians can use to plan treatment strategies for their advanced cancer patients and identifying the evidence in the public domain that justifies the
Slide 14: Multiple current and potential revenue sources
Multiple current and potential revenue sources Web and Mobile Apps Pharma Physicians and patients Pharma MedPage Today Per-test-fees(Software-as-a-Service) Volume-based Subscriptions Ad revenue / Sponsorships Customization(Fee for service) “Freemium” / PremiumSubscriptions Data analyticsLicense Fees
Slide 15: Long-term product strategy
Long-term product strategy Business Model Diagnostic Content Provider Outcomes Driver Early Adopter Oncologists & Pathologists Broader Provider User Base Payers / Pharma Content supplier for platform providers and related customers Initial penetration of diagnostic labsOnline media presence Stage I
Slide 16: Partnerships, strategic alliances, customers and sponsors
Partnerships, strategic alliances, customers and sponsors * Academic InstitutionsCancer CentersProfessional OrganizationsUniversity of ChicagoOhio State UniversityJackson LaboratoryOncoSolutions Cancer Center (Singapore)American Society of Clinical Oncology (ASCO)College of American Pathologists (CA
Slide 17: Seasoned leadership team
* Seasoned leadership team Thomas Mika, MBA; Chairman, President, and CEO – Tegal, IMTEC, Cresap, National Science Foundation, HBS George Lundberg, MD; Chief Medical Officer and Editor-in-Chief – AMA, WebMD, Medscape, Stanford (Professor, pathology), Lundberg InstituteClifford Baron, PhD; Vice Presi
Slide 18: Board of Directors
* Board of Directors Thomas R. Mika, Chairman (see Management Team)Paul R. Billings, MD, PhD – Author, lecturer, consultant, professor and thought leader in genomic medicine. CMO, Thermo Fisher Scientific, Member of FDA Science Board, VA Genomic Medicine Advisory Committee, IOM Genomic Medicine Roun
Slide 19: CollabRx, Inc. Balance Sheet
CollabRx, Inc. Balance Sheet6/30/14 © Copyright 2014 CollabRx, Inc. - All Rights Reserved NASDAQ CM: CLRX © Copyright 2014 CollabRx, Inc. - All Rights Reserved NASDAQ CM: CLRX *
Slide 21: Investment Thesis
Investment Thesis Highly regarded, industry-leading position with unique, proprietary platform to address critical need of interpretation and reporting on genomic test results to physicians at scaleDeveloped and published objective criteria for “Actionability” of genomic test results with high-profi

CollabRx — IPO Roadshow (November 2014) on 6ix

Rennova Health — CollabRx — IPO Roadshow (November 2014)

Slide 1: CollabRx: Empowering Cancer Care

Slide 2: Safe Harbor

Slide 3: Free Writing Prospectus Statement

Slide 4: Overview of CollabRx

Slide 5: Oncologists are our market

Slide 6: Newly emerging market for genomic-based testing in cancer

Slide 7: Need to address rapidly changing science and standards in oncology

Slide 8: GVA focused on knowledge-based portions of clinical genetic testing workflow

Slide 9: Therapy Finders make expert knowledge available at the office and at home

Slide 10: Combining in-house and external experts into a knowledge resource

Slide 11: Over 75 expert advisors from leading institutions

Slide 12: Minutes Not Days: GVA System

Slide 13: Competitive Strengths

Slide 14: Multiple current and potential revenue sources

Slide 15: Long-term product strategy

Slide 16: Partnerships, strategic alliances, customers and sponsors

Slide 17: Seasoned leadership team

Slide 18: Board of Directors

Slide 19: CollabRx, Inc. Balance Sheet

Slide 20: Capitalization

Slide 21: Investment Thesis

Slide 22: www.collabrx.com